
Ocuphire Pharma’s Nyxol treatment for pharmacologically-induced pupil dilation (mydriasis) has met its primary and secondary endpoints in its Phase III …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

